Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), a healthcare company developing and commercializing ...

Pharmaceutical companies in India are driving innovation, biosimilars, APIs & global exports while strengthening research, manufacturing & healthcare access.

Explore pharmaceutical companies to know 2026 delivering innovative pharmacy solutions and improving patient care across the U.S.

Midtown-based Dianthus Therapeutics announced a $625 million public offering this week to raise capital for anti-inflammatory drug development. The company, which specializes in treatments for ...

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal ...

If you are fried from constant fires at work but still need a real income, you are not alone. And there are careers that ...

It takes a long time, many different steps, and considerable cost, before a new drug can be approved for use as a medicine. One could be forgiven for thinking that, since billions of people across the ...

The data flowing through our hiring platform reveals a market that is no longer just ‘hiring for headcount’—it is hiring for pipeline certainty.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.

By Sriparna Roy and Sneha S K March 12 (Reuters) - Artificial intelligence is being deployed on both sides of the tug-of-war between U.S. healthcare systems that want to be paid more for medical ...

Q4 2025 Management View Leiv Lea, Chief Financial Officer, reported research and development expenses of $9.9 million in Q4 2025, attributing the increase to higher clinical trial and manufacturing ...

Biotech Immutep has scrapped clinical trials of its leading drug candidate, lung cancer treatment Efti, in a major blow for investors, including Phil King’s Regal Partners, which owns a 14 per cent ...